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Fig 1. A, Sharply demarcated erythematous plaques in a
70-year-old woman developed in the context of vemur-
afenib melanoma therapy. B, Histology demonstrated
interface dermatitis with follicular plugging and dermal
mucin deposition consistent with lupus erythematosuse
like eruption. (B, Hematoxylin-eosin stain; original magni-
fication: 320.)
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e160 Letterserythematosuselike pattern (Fig 1, B). Indirect
immunofluorescence showed elevated antinuclear
antibody titers (1:320). Muscle creatine kinase was
normal, which excluded the differential diagnosis of
paraneoplastic dermatomyositis. There was no
increased photosensitivity after 24 hours of ultravi-
olet A/B exposition. Moreover, photopatch testing
also showed no sign of belated, increased photo-
sensitivity after 4 weeks. Topical treatment of these
lupus-like plaques was implemented with topical
mometasone furoate cream that lead to gradual
recovery within 4 weeks. In addition, the patient
was instructed as to the careful use of sun blockers.
Over the course of time the underlying diseaseOpen access under CC BY-NC-ND license.progressed, with radiotherapy and chemotherapy
needed.
The clinical and the histologic presentations of
our patient are consistent with a lupus erythemato-
suselike skin eruption that was most likely associ-
ated with the vemurafenib therapy. A paraneoplastic
reaction cannot totally be excluded but would be
unusual in the context of malignant melanoma.
Although the patient did not show increased photo-
sensitivity we speculate that both the already well-
known side effect of photosensitivity that can be an
initial symptom of lupus erythematosus and the
lupus erythematosuselike skin eruptions mark a
spec-trum of vemurafenib-induced drug reactions.
The pathomechanism behind this reaction pattern
needs further investigations.
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Localized insulin-dependent amyloidosis with
scar-tissue formation
To the Editor: The incidence and prevalence of
diabetes mellitus has increased dramatically in the
last few years as a result of increasing prevalence of
Fig 1. Insulin-induced localized amyloidosis. A, Indurated erythematous subcutaneous lumps
on the lower abdominal quadrants. B, Hematoxylin and eosinestained skin biopsy specimen of
the subcutaneous mass showing fibrocollagenous scar tissue. C, Congo-red staining of the
fibrocollagenous scar tissue. D, Immunohistochemical staining for insulin of the fibrocollag-
enous scar tissue. Bars ¼ 100 m.
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Letters e161obesity, physical inactivity, and aging. In the course
of the disease nearly all patients develop skin
complications caused by the long-term effects of
diabetes mellitus.1 Sequelae can, however, also be
caused by the treatment regimen.
Here we describe the case of a 26-year-old male
patient with a 24-year history of type 1 diabetes
mellitus, who presented with 2 relocatable, indu-
rated subcutaneous lumps below his navel (Fig 1, A).
His treatment regimen included regular subcu-
taneous administration of insulin detemir and
insulin lispro, which he had habitually injected
into these nodules for 2 to 3 years. His
diabetic control was moderate (hemoglobin A1c
8.0%) and he had no diabetic long-term complica-
tions. For diagnostic purposes, 1 nodule was
excised. Histologic examination showed a highly
homogenized connective tissue with a depletion of
cells and vessels in the tumor area accompanied by
foci of necrobiosis and calcification (Fig 1, B).
Congo-red staining revealed the brick-red coloration
of amyloid within the subcutaneous nodule (Fig 1,
C ). Immunohistochemical staining for insulin
demonstrated that the amyloid fibrils originated
from insulin deposits (Fig 1, D).
Insulin-induced localized amyloidosis combined
with scar tissue is an underdiagnosed complication
of regular insulin injections in patients with insulin-
dependent diabetes. Only a few cases of localizedinsulin-derived amyloidosis have been described in
the literature2 and even fewer cases of insulin-
induced amyloid deposits were associated with
scar-tissue formation.3 In 1 case, insulin injections
caused scar-tissue formation without amyloid
depositions. Here, the authors suggested that the
scar tissue might be caused traumatically by the
repeated subcutaneous injections.4
The mechanism underlying insulin-derived
amyloid formation is not entirely clear. It has been
shown that insulin in the absence of its C-peptide can
assemble into fibrils and that an acidic environment
frequently found in scar tissue in combination with
high insulin concentrations can accelerate this
process.5
Compared with the well-known insulin-induced
lipohypertrophy, the nodules form more solid and
firm lesions, which do not resolve quickly after
rotation of the insulin injection site.3
Dermatologists should think of this differential
diagnosis when diabetic patients present with
firm nodes at the injection site, as regular
insulin injections in these subcutaneous nodules
can be associated with poor diabetic control.
In addition, the presence of scar tissue in
localized insulin-induced amyloidosis is worth
mentioning as the low pH present in this environ-
ment might trigger insulin-derived amyloid
formation.
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